Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | STAT1 | P42224 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6055638 | 0.85 | GABRB3 (0.41) | SMN1; SMN2LMNA | |
| SCHEMBL6965005 | 0.79 | ALDH1A1 (0.45) | POLBSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL6967472 | 0.76 | GABRB3 (0.45) | SMN1; SMN2LMNA | |
| SCHEMBL7972335 | 0.75 | GABRB3 (0.40) | SMN1; SMN2LMNA | |
| SCHEMBL6968989 | 0.75 | ALDH1A1 (0.44) | POLBSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL6055634 | 0.75 | GABRB3 (0.43) | SMN1; SMN2LMNA | |
| SCHEMBL6976275 | 0.74 | GABRB3 (0.41) | SMN1; SMN2LMNA | |
| SCHEMBL6973180 | 0.74 | SRC (0.30) | — | |
| SCHEMBL6976804 | 0.74 | GABRA2 (0.40) | SMN1; SMN2LMNA | |
| SCHEMBL6969849 | 0.74 | GABRA2 (0.40) | SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060105969-A1 | Anthelmintic compositions | BRUCE CHRISTOPHER I | 2006-05-18 | — | — | US | claimed |
| EP-0946515-B1 | PARASITICIDAL PYRAZOLES | PFIZER LTD (GB) | 2003-03-05 | — | — | EP | claimed |
| US-6075043-A | Parasiticidal pyrazoles | PFIZER INC. (US) | 2000-06-13 | — | — | US | claimed |
| EP-0946515-A1 | PARASITICIDAL PYRAZOLES | Pfizer Limited (GB) | 1999-10-06 | — | — | EP | claimed |
| WO-1998024767-A1 | PARASITICIDAL PYRAZOLES | PFIZER LIMITED (GB) | 1998-06-11 | — | — | WO | claimed |
| US-20060105969-A1 | Anthelmintic compositions | BRUCE CHRISTOPHER I | 2006-05-18 | — | — | US | disclosed |
| EP-0933363-B1 | Parasiticidal pyrazoles | PFIZER LTD (GB) | 2003-08-27 | — | — | EP | disclosed |
| EP-0946515-B1 | PARASITICIDAL PYRAZOLES | PFIZER LTD (GB) | 2003-03-05 | — | — | EP | disclosed |
| US-20020173662-A1 | Parasiticidal pyrazoles | BANKS BERNARD JOSEPH (GB) | 2002-11-21 | — | — | US | disclosed |
| US-6268509-B1 | PESTICIDES | PFIZER INC | 2001-07-31 | — | — | US | disclosed |
| US-6090394-A | FOR HUMANS, ANIMALS | PFIZER INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-6075043-A | Parasiticidal pyrazoles | PFIZER INC. (US) | 2000-06-13 | — | — | US | disclosed |
| US-6019986-A | Parasiticidal pyrazoles | PFIZER INC. (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0946515-A1 | PARASITICIDAL PYRAZOLES | Pfizer Limited (GB) | 1999-10-06 | — | — | EP | disclosed |
| EP-0933363-A1 | Parasiticidal pyrazoles | Pfizer Limited (GB) | 1999-08-04 | — | — | EP | disclosed |
| WO-1998024767-A1 | PARASITICIDAL PYRAZOLES | PFIZER LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105969-A1 | Anthelmintic compositions | TUBB, TUBA3C, CYP51A1 | POLB 1424/4885SMN1; SMN2 4582/4885ALDH1A1 1903/4885 |
| US-20020173662-A1 | Parasiticidal pyrazoles | HRH3, HRH2, HRH1 | POLB 4325/4885SMN1; SMN2 4644/4885ALDH1A1 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.